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Abstract
Background: Haemophilias are the most common hereditary severe disorders of blood clotting.
In families afflicted with heamophilia, genetic analysis provides opportunities to prevent recurrence
of the disease. This study establishes a diagnostical strategy for carriership determination and
prenatal diagnostics of haemophilia A in Bulgarian haemophilic population.
Methods: A diagnostical strategy consisting of screening for most common mutations in the factor
VIII gene and analysis of a panel of eight linked to the factor VIII gene locus polymorphisms was
established.
Results: Polymorphic analysis for carrier status determination of haemophilia A was successful in
30 families out of 32 (94%). Carrier status was determined in 25 of a total of 28 women at risk
(89%). Fourteen prenatal diagnoses in women at high risk of having a haemophilia A – affected child
were performed, resulting in 6 healthy boys and 5 girls.
Conclusion: The compound approach proves to be a highly informative and cost-effective strategy
for prevention of recurrence of haemophilia A in Bulgaria. DNA analysis facilitates carriership
determination and subsequent prenatal diagnosis in the majority of Bulgarian families affected by
haemophilia A.
Background
Haemophilia A is a common inherited disorder of blood
clotting, inherited in a recessive X-linked pattern. The inci-
dence of the disease is estimated at app. 1:8000 males.
Affected individuals develop a variable phenotype of
hemorrhage into joints and muscles, easy bruising, and
prolonged bleeding from wounds. The severity and fre-
quency of bleeding in heamophilia A is inversely related
to the amount of residual factor.
Haemophilia A is caused by deficiency of factor VIII, a
cofactor in the activation of factor X at the middle stages
of the coagulation cascade. The gene coding for factor VIII
is located in the subtelomeric Xq28 region, comprises 26
exons and spans 186 kb genomic DNA [1,2].
By the present moment over 400 mutations leading to
haemophilia A have been identified [3,4]. De novo muta-
tions in the factor VIII gene constitute a significant pro-
portion of haemophilia A cases (app. 30% of all cases)
[5]. Half of such mutations do not derive from a single
germ cell but are attributed to a germline or somatic
mosaic originating from a mutation during early embryo-
genesis [6,7].
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In approximately 40–50% of the severe cases (25% of all
cases) the underlying molecular defect causing haemo-
philia A is a gross rearrangement of the gene owing to
intrachromosomal homologous recombination between
inverted repeats located in intron 22. and outside the
gene. Recombination leads to separation of exons 1. – 22.
from exons 23. – 26. and positioning these in reverse ori-
entation to the remaining part of the gene [8,9]. Several
types of inversion have been recognized. Most often
encountered is inversion type I, which involves the distal
copy of the repeated unit, but types II (involves the prox-
imal copy) and III (when more than two extragenic copies
of the repeated unit are present) are also common in hae-
mophilia A patients [10,11].
Transition mutations C→T (respectively, G→A) in CpG
dinucleotides of factor VIII gene occur frequently [12].
Thus, screening for mutations abolishing or creating
restriction sites in patients with severe haemophilia A can
provide direct carrier detection. Screening for unknown
mutations is also accomplished by various scanning
methods (such as SSCA) and subsequent sequencing of
fragments which show abnormal electrophoretic pattern
[13,14].
Large inversions can be detected by either Southern
hybridisation or nested RT-PCR spanning the breakpoint
in intron 22. analysis and thus carrier and/or antenatal
diagnosis is accomplished [10,15]. Because of the enor-
mous variety of mutations producing the disease in the
remaining 75% of cases (except for the large inversions),
carrier identification and prenatal diagnosis can be
accomplished by indirect detection using linked to the
disease locus DNA polymorphisms. A number of RFLPs
and tandem repeats have been identified within the genes
of factor VIII and in its extragenic regions [16-23].
Rapid carriership determination and prenatal diagnosis
are usually facilitated by a compound diagnostical strat-
egy consisting of screening for the large inversions com-
bined with DNA analysis of polymorphisms within and
outside the factor VIII gene. DNA analysis using polymor-
phic markers linked to disease locus proves to be highly
effective, as the proportion of cases in which linkage anal-
ysis fails is less than 20% of the affected families [24-26].
In Bulgaria, the incidence of haemophilia A is estimated
to be about 1:18 000 live births (1:9000 males) [27]. The
mainstay of treatment for bleeding episodes in Bulgarian
haemophiliacs is "treatment on demand", e. g. applica-
tion of the deficient factor at the first symptom of bleed-
ing. Considering the short half-life of factor VIII in
plasma, most of the time the haemophiliacs in Bulgaria
live and function far below therapeutic levels of deficient
factor. This poses a constant risk of sudden hemorrhage
that might be difficult to handle. Thus, despite recent
marked improvement in treatment of bleeding disorders,
for Bulgarian patients, haemophilia remains a severe, crip-
pling, sometimes life-threatening disease.
Carriership of haemophilia invariably has influence on
women's reproductive plans. It is documented elsewhere
that approximately 50% of female relatives of haemo-
philia patients may decide consciously not to have chil-
dren and relate their decision to fear of passing the disease
to their children [28,29]. DNA analysis greatly improves
the effectiveness of early determination of carrier status.
The main goal of this study was to investigate the genetic
heterogeneity of haemophilia A in Bulgaria in order to
construct effective diagnostical strategy for prevention of
recurrent disease in families already affected.
Methods
DNA samples
Thirty-two haemophilia A families consisting of 162
members with 36 haemophilia A-affected males were
included in the present study. Twenty-two of the families
(69%) did not have previous history of haemophilia A.
The distribution of clinical severity of haemophilia A was
as follows: 23 patients (64%), severe (FVIII:C <1%); 8
patients (22%), moderate (FVIII:C 1 – 5%) and 5 patients
(14%), mild (FVIII:C >5%).
Written informed consent was obtained from all haemo-
philia patients and their relatives that participated in the
study. In the case of minors, informed consent for partic-
ipation in genetic studies was obtained from their parents
or legal guardians.
DNA was extracted from 5 ml peripheral blood or fetal
material. For PCR purposes, DNA was prepared by protei-
nase K digestion/phenol extraction/ethanol precipitation
as described in [30]. For genomic hybridisation, high
molecular weight DNA was obtained by embedding leu-
cocytes in low-melting agarose blocks and subsequent
digestion by proteinase [30].
Fetal DNA was extracted from 3–10 mg chorionic villi
obtained by chorionic villus sampling (CVS) at 10.–12.
week of gestation (g. w.) or from 10–15 ml amniotic liq-
uid obtained by amniocentesis at 16.–21. g. w., after
informed consent.
Southern hybridisation for detection of factor VIII 
inversions
High molecular weight genomic DNA (3–6 µg) was
digested with Bcl I, separated by agarose electrophoresis
and blotted onto nylon membrane. DNA probe was
obtained either by digestion of p542.16 with Eco RI/Sac IBMC Blood Disorders 2004, 4 http://www.biomedcentral.com/1471-2326/4/2
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[9]; or by amplification of the desired region of the intron
22. using genomic DNA from healthy male volunteers
[31]. PCR fragment was purified by low-melting point
agarose elution. Filling-end reaction was performed with
Klenow fragment, though the probe can be used without
the ends – blunting step. The hybridisation probes were
labeled to high specific activity by random priming. Blots
were hybridized at 64° C in modified Church's buffer: (5
X SSC, 50 mM Na2HPO4; pH = 7,2; 10% dextran sulphate;
6% SDS and washed twice with 2 X SSC, 0,1% SDS at
room temperature, and twice with 0,1 X SSC, 0,1% SDS at
the hybridisation temperature [9]. Autoradiography was
carried out at -70° C.
Analysis of DNA polymorphisms linked to Factor VIII gene 
locus (gene tracking)
PCR analysis of tandem repeats
Tandem repeats in extragenic region of factor VIII gene
(St14) and inside the gene (intron 13. (IVS13(CA)nSTR,
IVS13STR), intron 22. (IVS22(CA)nSTR, IVS22STR),
intron 25. (IVS25(CA)nSTR, IVS25STR) (Universitat fur
Humangenetik-Muenster, Germany-personal communi-
cation) and intron 6. (IVS6(CA), IVS6STR) were used in
the present study [16,21-23]. PCR products were sepa-
rated in 6–10% nondenaturing (or sequencing) polyacry-
lamide gels and visualised by silver staining [32] or by
autoradiography.
PCR-RFLP polymorphisms
Polymorphic sites in intron 18. (Bcl I RFLP); intron 19.
(Hind III RFLP), intron 22. (Xba I RFLP) of the factor VIII
gene were used in the present study [16,17,20,21]. PCR
products were subjected to restriction with the relevant
restriction endonuclease, separated in nondenaturing
polyacrylamide gels and visualised by silver staining.
G/A polymorphism in intron 7. of the factor VIII gene
The region containing the polymorphic site was amplified
according to [18]. Samples were denatured and electro-
phoresed on a 14% polyacrylamide gel (37,5:1 acryla-
mide:bisacrylamide) at 5° C for 20 h and visualised by
silver staining.
Screening for mutations in the essential regions of the 
factor VIII gene
SSCA analysis
Exons 11., 14. and 24. of the gene of the Factor VIII gene
were screened for mutations as described in [14]. PCR
yielded 343 bp fragment for exon 24. and 445 bp frag-
ment for exon 11., respectively. The large exon 14. was
amplified as four overlapping fragments, app. 1000 bp
long. The resulting amplification fragments were hydro-
lyzed with the Alu I. Digested samples were denatured and
electrophoresed on a 14% polyacrylamide gel (37,5:1 acr-
ylamide:bisacrylamide) at 8°C for 20 h and visualized by
silver staining. Sequencing of the fragments was per-
formed by the dideoxy chain-termination method, on
AbiGene automatic sequencer (Applied Biosystems).
Screening for restriction site abolishing mutations in exons 1. and 18
Screening for Taq I site abolishing mutations in exon 1.
and Taq I/Rsa I site abolishing mutations in exon 18. of
the Factor VIII gene was performed according to [12].
Briefly, the PCR amplification yielded 186 bp fragment
for exon 1. and 291 bp fragment for exon 18., respectively.
Normally, Taq I digestion of the PCR fragment of exon 1.
results in fragments 165 and 21 bp. C→T transition in
exon 1. abolishes the existing Taq I restriction site.
In exon 18. normally exists 1 restriction site for Taq I
(digestion pattern of 163 and 128 bp) and 2 sites for Rsa
I (digestion pattern of 207, 57 and 32 bp). Transition
C→T results in abolishment of the Taq I site and one of
the Rsa I sites I (digestion pattern of 234 and 57 bp).
Results and discussion
Screening for most common mutations causing severe 
haemophilia A
Inversion mutation was found in 13 out of 29 severe and
severe-to-moderate haemophilia A patients (45%, 0.95%
CI: 28,4–62,5%). Ten of these carried the common type of
inversion (type I), involving the distal extragenic copy of
the repeated unit (77%), two patients (15%) – inversion,
involving the proximal copy of the 9,5 kb repeat (type II)
and 1 patient carried the rare type IIIB inversion.
Analysis of DNA polymorphisms linked to factor VIII gene 
locus
By genealogical data, 28 women (not including mothers
of haemophilia A boys) were identified to be at risk to be
carriers of haemophilia A.
Polymorphic analysis for carrier status determination of
haemophilia A was successful in 30 families out of 32
(94%).
These families were informative by at least one marker
locus. In 5 families (16%) only the extragenic DNA
marker St14 was informative. Only 2 families (6%) were
uninformative by all the markers used. Rates of heterozy-
gocity for polymorphic markers used are shown in table 1.
Among markers internal to factor VIII, intron 22 dinucle-
otide repeat showed highest heterozygocity rate (H) of
0,63, followed by intron 13 repeat (0,46), that renders
these two very useful and reliable for diagnostic purposes
in Bulgarian population. Intron 22 STR was informative
in 19 of 32 families (60%, 0.95% CI: 42,2–74,5%). IntronBMC Blood Disorders 2004, 4 http://www.biomedcentral.com/1471-2326/4/2
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13 STR was informative in 12 of 32 families (38%, 0.95%
CI: 22,9–54,8%).
Biallelic polymorphisms Hind III and Bcl I RFLP follow as
markers of choice in the Bulgarian population as their het-
erozygocity is 0,35. This marker system was informative in
14 of 32 families (45%, 0.95 CI: 28,1–60,7%).
Intron 25 dinucleotide repeat was informative in 7 of 32
families (21%, 0.95 CI: 11,0–38,7%). This marker exhib-
ited a rare allele, (150 bp long, a CA22 repeat) in the
cohort of Bulgarian patients. This allele was observed only
in one of the 65 independent X-chromosomes studied
and is presumed to be quite rare (1,5%, 0.95 CI 0,27 –
8,22%). IVS25STR has limited applicability in most cases,
because of its low heterozygocity rate (0,25). Neverthe-
less, as the gene for factor VIII is quite large and recombi-
nation within the limits of the gene itself is possible, when
informative, IVS25STR may serve as an useful genetic
marker in the distal part of the gene.
Intron 7 G/A SSCA polymorphism was informative in 6 of
32 families (19%, 0.95% CI: 8,9–35,3%). This marker
exhibited in Bulgarian patients' heterozygocity rate even
lower than the intron 25 dinucleotide repeat system
(0,19). After typing with a panel of IVS22STR – HindIII/
BclI system – Xba I RFLP – IVS25STR, intron 7 SSCA hap-
lotype data does not add to the proportion of cases in
which at least one marker is informative (Fig. 1).
IVS6STR dinucleotide repeat exhibits very low polymor-
phism in the Bulgarian haemophilic population.(hetero-
zygocity rate of 0,02). We observed three alleles with 12–
14 repetitions (CA)(12–14). Single allele ((CA)13) accounts
for 99% of all alleles. This renders the marker less useful
for the diagnosis of haemophilia A carriers.
St14 VNTR, with its large number of alleles (10 observed
in this study out of 15 described in [21]) proves to be the
most informative marker in the Bulgarian population. It
was informative in 29 of 32 families (91%, 0.95% CI:
75,8–96,8%) and has the highest heterozygocity rate
(0,78) of all the polymorphic markers included in this
study.
St14 may solve the diagnostic problem in cases when
none of the intragenic markers is informative. As it is
located approximately 2 map units apart from the factor
VIII locus, recombination rate is estimated at 2% per mei-
osis. Rarely, recombination between marker locus and
disease gene locus may occur. We have observed one such
case (data not shown).
Screening for mutations in the essential regions of the 
factor VIII gene
SSCA analysis
SSCA can detect over 95% of causative mutations in mod-
erate and mild haemophilia A and about 50% of the
defects that cause severe haemophilia A (as large rear-
rangements account for app. 50% of the severe cases)
[13,14,33].
Exons 11., 14. and 24. of the gene of the Factor VIII gene
in 34 males with haemophilia A were screened by SSCA
and subsequent sequencing. No pattern different from the
normal was found.
Restriction analysis
Screening for Taq I abolishing mutations in exon 1 and
Taq I/Rsa I site abolishing mutations in exon 18. of the
factor VIII gene was performed. Two related patients were
found to carry a Taq I site abolishing mutation in exon I,
resulting in CGA-to-TGA (Arg to Stop) transition in the
vicinity of transcription startpoint of the factor VIII gene.
This molecular defect resulted in these patients in severe
phenotype with practically undetectable plasma levels of
factor VIII.
Conclusions
Severe form of haemophilia A accounts for over 60% of
Bulgarian patients in this study. As no founder effect pat-
tern could be established, this biased pattern may be due
to undereferral of moderate and mild haemophiliacs. This
may reflect the fact that some milder cases may escape
clinical attention. In fact, some researchers estimate the
Table 1: The panel of factor VIII gene linked polymorphisms, used as markers for carriership determination and prenatal diagnostics of 
haemophilia A in Bulgaria and their local heterozygocity rates.
Marker ST14 VNTR IVS22 STR IVS13 STR BclI RFLP HindIII RFLP XbaI RFLP IVS25 STR Int7 G/A IVS6 STR
H* 0.78 0.63 0.46 0.35 0.35 n.a.** 0.25 0.19 0.02
*H: heterozygocity rate. (H = 1 - 931;pi
2); pi – frequency of allele i. **The sequence containing the Xba I polymorphic site is located in the 9,5 kb 
repeated region of intron 22. Thus, flanking primers amplify together with the Xba I polymorphic site a fragment in the extragenic copies that 
usually lack the Xba I restriction site and, practically, genotypes +/+ cannot be distinguished of genotype +/-. Thus, genotype of a female must be 
inferred of the genotype of her children [19].BMC Blood Disorders 2004, 4 http://www.biomedcentral.com/1471-2326/4/2
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real incidence of haemophilia A [1] to be 1:5000 males,
that is, almost twice as high as the current value.
Gross inversions of the factor VIII were discovered in 45%
of Bulgarian cases of severe and severe-to moderate hae-
mophilia A (36% of all). In the remaining severe cases as
well as in the moderate and mild haemophilia A, the anal-
ysis of polymorphisms linked to the factor VIII gene
proved as an invaluable tool in carrier status determina-
tion and prenatal diagnosis. In Bulgarian patients, com-
bined use of analysis of DNA polymorphisms linked to
factor VIII locus and screening for inversion mutation
failed only in 2 cases (6%).
Fig. 1. presents a plot of cumulative informativeness of the
markers included in this study vs. increasing number of
markers used for haplotyping. Additional number of
intragenic markers does not increase the percentage of
informative families beyond 72%. Including the external
marker St14 will raise the overall informativeness up to
94%, nevertheless, the risk of recombination between
extragenic marker and disease locus may become signifi-
cant depending on the number of meioses in question.
Carrier status was determined in 25 of a total of 28
women at risk (89%). One woman dropped out of study
when she became pregnant. In 2 women (7%) DNA anal-
ysis gave no information about the type of mutation and
tracking of the defective gene failed because of lack of het-
erozygocity of the polymorphic markers. In thirteen
women carriership of haemophilia A was ruled out. In the
remaining 12 women, carriership for haemophilia A was
confirmed.
Fourteen prenatal diagnoses in women at high risk of hav-
ing a haemophilia A – affected child were performed.
These pregnancies produced 6 boys and 5 girls (two carri-
ers, two noncarriers, and one where no further DNA anal-
A plot of cumulative informativeness of panel of markers linked to factor VIII locus used for polymorphic DNA analysis of hae- mophilia A in Bulgaria Figure 1
A plot of cumulative informativeness of panel of markers linked to factor VIII locus used for polymorphic DNA analysis of hae-
mophilia A in Bulgaria. By polymorphic DNA analysis of the factor VIII gene locus carrier status of females in 30 Bulgarian fam-
ilies out of 32 (94%) could be determined. Intron 22. and intron 13. STR dinucleotide repeats used together are informative in 
64% of haemophilia A families. Adding biallelic Hind III/Bcl I RFLP polymorphic system and Xba I PFLP results in further increase 
in percentage of informative families up to 70%. IVS25STR marker is informative in a limited proportion of cases (increases 
informativeness up to 72% of the families). Intron 7. SSCA haplotype data does not add to the proportion of cases in which at 
least one marker is informative. St14 tandem repeat exhibits the highest heterozygocity rate of all factor VIII gene linked mark-
ers and thus proves to be the most informative marker in the Bulgarian population. St14 is a marker of choice in cases when 
none of the intragenic markers is informative, nevertheless, its location apart of factor VIII gene poses risk of misdiagnosis due 
to marker-to-gene recombination.
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ysis after fetal sex determination was carried out). Five of
the boys were healthy. In one case with pregnancy with
male fetus, a key recombination between extragenic and
intragenic for Factor VIII gene polymorphic markers was
discovered. As the haemophiliac male was the first and
only case in this family and no DNA was available from
him, mutation screening could not be accomplished and
no definite conclusion could be drawn from the polymor-
phic DNA analysis. The parents decided not to terminate
the pregnancy, as the mother was in 22. g. w. by the end
of analysis.
In two cases, the fetus was found to be at high risk to be
affected by haemophilia A. In both cases, parents invaria-
bly chose termination of the pregnancy.
In one case CVS produced insufficient amount of material
for DNA analysis and biopsy was repeated, which led to
obstetrical complications, and, finally, to loss of fetus.
Screening for gross inversions disrupting factor VIII gene
combined with analysis of a panel of DNA markers linked
to the disease locus proves to be highly informative and
cost-effective strategy for prevention of recurrence of hae-
mophilia A in Bulgaria. This compound approach facili-
tates carriership determination and subsequent prenatal
diagnosis in the majority of Bulgarian haemophilia A
families.
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H Heterozygocity rate
PCR Polymerase chain reaction
RFLP Restriction fragment length polymorphism
SSCA  Analysis of conformation single-stranded DNA
fragments
STR Short tandem repeat
VNTR Variable number of tandem repeats
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